Retinal Sensitivity in BRVO After Anti-VEGF Therapy

Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02527733

Enrollment

Registered

2015-08-19

Start date

2015-06-30

Completion date

Unknown

Last updated

2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch Retinal Vein Occlusion

Brief summary

The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.

Interventions

DRUGRanibizumab

DRUGRanibizumab and laser

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Treatment naive patients of branch retinal vein occlusion with visual acuity of less than 1.0 and macular edema of more than 250 micrometers in foveal thickness.

Exclusion criteria

* Patients with history of treatment for branch retinal vein occlusion, possibility of pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will be excluded.

Design outcomes

Primary

Measure	Time frame
Retinal sensitivity measured by microperimetry (MP-3, NIDEK, Japan)	At 12 months

Countries

Japan

Contacts

Primary ContactAkira Ojima, M.D., Ph.D

ao@fmu.ac.jp+81-24-548-2111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026